Balance Sheet

v3.22.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Current assets:    
Cash $ 64,553 $ 85,838
Restricted cash 148,613 0
Accounts receivable, net 10,393 1,500
Grant receivable 209,350 56,359
Prepaid expenses 154,587 84,629
Total current assets 587,496 228,326
Property and equipment, net 96,275 102,843
Right to use assets 357,246 384,921
Other assets:    
Patents, net 11,090 11,385
Software development costs 47,980 47,980
Deposits, long term 44,520 44,520
Total other assets 103,590 103,885
Total assets 1,144,607 819,975
Current liabilities:    
Accounts payable and accrued expenses, including related party payables of $1,128,058 and $1,014,892, respectively 3,227,392 3,188,560
Deferred revenue, short term 34,981 34,981
Lease liability, short term 123,269 119,733
Notes payable 221,480 221,480
Notes payable, related parties 790,110 790,110
PPP loan, short term 15,373 31,580
Total current liabilities 4,412,605 4,386,444
Long term liabilities:    
PPP loan, long term 116,067 99,860
EIDL loan, long term 74,300 74,300
Royalty obligation, net of discount of $5,738,892 and $5,854,226, related parties 2,983,208 2,867,874
Lease liability, long term 283,307 315,672
Deferred revenue, long term 28,675 37,301
Total liabilities 7,898,162 7,781,451
Deficit:    
Common stock, $0.001 par value; 750,000,000 shares authorized, 6,954,277 and 6,698,968 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively 6,954 6,699
Common stock subscribed 100,000 100,000
Additional paid in capital 64,147,396 62,994,739
Accumulated deficit (70,911,132) (69,966,692)
Total deficit attributable to BioCorRx, Inc. (6,635,166) (6,843,638)
Non-controlling interest (118,389) (117,838)
Total deficit (6,753,555) (6,961,476)
Total liabilities and deficit 1,144,607 819,975
Series A Convertible Preferred Stock    
Deficit:    
Preferred stock, value 16,000 16,000
Series B Convertible Preferred Stock    
Deficit:    
Preferred stock, value $ 5,616 $ 5,616

Source